| Transforming ‘Regulation’—a structural hurdle in the biopharma industry—into an opportunity for innovation via dedicated teams
| Biopharma industry emerges as a future national growth engine... Wave of strategic corporate changes aligning with government’s comprehensive support plan
| JNPMEDI launches dedicated regulatory compliance team to address environmental changes... Providing practical support via proactive management
| Companies accelerate securing future leadership through structural innovation, including dedicated AI units and R&D reorganization
Previously, the pharmaceutical and biotech industry faced complex regulations and rapidly changing environments, often cited as structural barriers hindering corporate growth and innovation. Companies are now moving beyond passive or temporary responses, intensifying strategic efforts to address these structural hurdles by establishing or reorganizing dedicated teams based on their unique competitiveness.
This trend is gaining momentum, aligning with the government's initiative to foster the biopharma industry as a future national growth engine. Companies are securing specialized teams in areas requiring strategic operation—such as regulatory compliance, AI, and R&D—and building new competitive advantages based on advanced expertise. Dedicated teams, initially formed to respond to rapid regulatory and industrial changes, are gradually expanding their roles as strategic drivers for companies.
In fact, major companies are not merely solving individual challenges like strengthening responsiveness to regulatory bodies, overhauling internal management systems, or developing tech-based new drugs. They are accelerating innovation through reorganization, including the launch of dedicated teams, to leverage these capabilities as core corporate competitiveness.
■ JNPMEDI Transforms ‘Regulatory Barriers’ into ‘Competitiveness’... Operates Dedicated Compliance Service Team
JNPMEDI, an AI platform-based clinical trial consulting firm, has launched a ‘Dedicated Compliance Service Team’ to address changes in the regulatory environment. Amid rising demands for ethical management and enhanced transparency across the domestic pharmaceutical, biotech, and medical device industries, this team aims to strengthen support for corporate compliance management and minimize legal risks.
Previously, companies faced difficulties such as legal risks stemming from inconsistencies or interpretation differences during data submission, especially in an environment of intensified regulatory oversight. To proactively resolve these issues, JNPMEDI launched this dedicated team, led by JaeHyun Lee, formerly of Kim & Chang Law Firm's Healthcare & Compliance Team, and HyunKwon Choi, former QA (Quality Assurance) lead at Pfizer HQ. They provide comprehensive support, ranging from establishing expenditure standards based on the Pharmaceutical Affairs Act and Medical Device Act to drafting reports and setting up internal management systems.
Furthermore, aiming to help companies complete reports suitable for actual submission to regulatory agencies, the team provides substantive support for establishing corporate compliance management systems. Through this organizational reinforcement centered on expert personnel, JNPMEDI plans to continuously contribute to ensuring transparency and establishing an ethical management culture in the healthcare industry.
| Transforming ‘Regulation’—a structural hurdle in the biopharma industry—into an opportunity for innovation via dedicated teams
| Biopharma industry emerges as a future national growth engine... Wave of strategic corporate changes aligning with government’s comprehensive support plan
| JNPMEDI launches dedicated regulatory compliance team to address environmental changes... Providing practical support via proactive management
| Companies accelerate securing future leadership through structural innovation, including dedicated AI units and R&D reorganization
Previously, the pharmaceutical and biotech industry faced complex regulations and rapidly changing environments, often cited as structural barriers hindering corporate growth and innovation. Companies are now moving beyond passive or temporary responses, intensifying strategic efforts to address these structural hurdles by establishing or reorganizing dedicated teams based on their unique competitiveness.
This trend is gaining momentum, aligning with the government's initiative to foster the biopharma industry as a future national growth engine. Companies are securing specialized teams in areas requiring strategic operation—such as regulatory compliance, AI, and R&D—and building new competitive advantages based on advanced expertise. Dedicated teams, initially formed to respond to rapid regulatory and industrial changes, are gradually expanding their roles as strategic drivers for companies.
In fact, major companies are not merely solving individual challenges like strengthening responsiveness to regulatory bodies, overhauling internal management systems, or developing tech-based new drugs. They are accelerating innovation through reorganization, including the launch of dedicated teams, to leverage these capabilities as core corporate competitiveness.
■ JNPMEDI Transforms ‘Regulatory Barriers’ into ‘Competitiveness’... Operates Dedicated Compliance Service Team
JNPMEDI, an AI platform-based clinical trial consulting firm, has launched a ‘Dedicated Compliance Service Team’ to address changes in the regulatory environment. Amid rising demands for ethical management and enhanced transparency across the domestic pharmaceutical, biotech, and medical device industries, this team aims to strengthen support for corporate compliance management and minimize legal risks.
Previously, companies faced difficulties such as legal risks stemming from inconsistencies or interpretation differences during data submission, especially in an environment of intensified regulatory oversight. To proactively resolve these issues, JNPMEDI launched this dedicated team, led by JaeHyun Lee, formerly of Kim & Chang Law Firm's Healthcare & Compliance Team, and HyunKwon Choi, former QA (Quality Assurance) lead at Pfizer HQ. They provide comprehensive support, ranging from establishing expenditure standards based on the Pharmaceutical Affairs Act and Medical Device Act to drafting reports and setting up internal management systems.
Furthermore, aiming to help companies complete reports suitable for actual submission to regulatory agencies, the team provides substantive support for establishing corporate compliance management systems. Through this organizational reinforcement centered on expert personnel, JNPMEDI plans to continuously contribute to ensuring transparency and establishing an ethical management culture in the healthcare industry.